UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 24, 2025
Artiva Biotherapeutics, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware |
|
001-42179 |
|
83-3614316 |
(State or other jurisdiction of incorporation) |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
5505 Morehouse Drive, Suite 100
San Diego, California 92121
(Address of principal executive offices)
Registrant’s telephone number, including area code: (858) 267-4467
N/A
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class |
|
Trading symbol(s) |
|
Name of each exchange on which registered |
Common Stock, $0.0001 par value per share |
|
ARTV |
|
Nasdaq Global Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 |
Results of Operations and Financial Condition. |
On March 24, 2025, Artiva Biotherapeutics, Inc. (“Artiva”) issued a press release announcing its financial results for the year ended December 31, 2024. A copy of the press release is attached hereto as Exhibit 99.1.
The information contained under this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or under the Exchange Act, regardless of any general incorporation language in any such filing, unless Artiva expressly sets forth in such filing that such information is to be considered “filed” or incorporated by reference therein.
Item 9.01 |
Financial Statements and Exhibits. |
(d) Exhibits.
|
|
|
Exhibit No. |
|
Description |
|
|
|
99.1 |
|
|
|
|
|
104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
Artiva Biotherapeutics, Inc. |
||
|
|
|
By: |
|
/s/ Fred Aslan |
|
|
Fred Aslan, M.D. |
|
|
President and Chief Executive Officer |
Dated: March 24, 2025
Exhibit 99.1
Artiva Biotherapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights
Initial data for AlloNK® from autoimmune program expected H1 2025
Updated clinical data from Phase 1/2 trial exploring AlloNK + rituximab in NHL showing continued durability of response to be presented at a medical conference in 2025
Strengthened key leadership with cell therapy and autoimmune expertise across organization
Robust balance sheet with cash, cash equivalents and investments of $185.4 million as of December 31, 2024, is expected to fund operations at least through end of 2026
SAN DIEGO, March 24, 2025 -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced financial results for the full year ended December 31, 2024, and highlighted recent progress.
“2024 was a transformational year for Artiva including initiating dosing of AlloNK® in patients with autoimmune disease across our trials, a successful initial public offering strengthening our balance sheet, and expanding key leadership across the organization with expertise in cell therapy and autoimmune disease,” said Fred Aslan, M.D., CEO of Artiva. “We look forward to sharing initial data from our AlloNK® program in autoimmune disease this year. We also look forward to sharing updated clinical data from our non-Hodgkin’s lymphoma (NHL) trial with AlloNK® which continues to mature as one of the strongest data sets for the allogeneic field, demonstrating deep B-cell depletion, continued durability of response, and the compatibility of our treatment regimen with outpatient administration.”
Recent Business Highlights
Corporate and Financial Updates
Upcoming Milestones
Full Year 2024 Financial Results
About Artiva Biotherapeutics
Artiva is a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers. Artiva’s lead program, AlloNK®, is an allogeneic, off-the-shelf, non-genetically modified, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity effect of monoclonal antibodies to drive B-cell depletion. AlloNK® is currently in clinical trials for treatment of systemic lupus erythematosus, for patients with or without lupus nephritis, and in an investigator-initiated basket trial in multiple autoimmune indications. Artiva’s pipeline also includes CAR-NK candidates targeting both solid and hematologic cancers. Artiva was founded in 2019 as a spin out of GC Cell, formerly GC Lab Cell Corporation, a leading healthcare company in the Republic of Korea, pursuant to a strategic partnership granting Artiva exclusive worldwide rights (excluding Asia, Australia and New Zealand) to GC Cell’s NK cell manufacturing technology and programs.
Artiva is headquartered in San Diego, California. For more information, please visit www.artivabio.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding: expectations of Artiva Biotherapeutics, Inc. (the “Company”) regarding the potential benefits, accessibility, effectiveness and safety of AlloNK®; the Company’s ability to advance AlloNK® in autoimmune disease; the Company’s expectations regarding timing and availability of data from the Company’s clinical trials or the IIT; the Company’s future results of operations and financial position, including cash runway; and the Company’s presentation plans. These forward-looking statements are based on the beliefs of the management of the Company as well as assumptions made by and information currently available to the Company. Such statements reflect the current views of the Company with respect to future events and are subject to known and unknown risks and uncertainties. In light of these risks and uncertainties, the events or circumstances referred to in the forward-looking statements may not occur. These and other factors that may cause the Company’s actual results to differ from current expectations are discussed in the Company’s filings with the Securities and Exchange Commission (the “SEC”), including the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date this press release is given. Except as required by law, the Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.
Artiva Biotherapeutics, Inc.
Condensed Balance Sheets
(unaudited)
(in thousands)
|
|
December 31, |
|
|
December 31, |
|
||
Assets |
|
|
|
|
|
|
||
Cash, cash equivalents and investments |
|
$ |
185,428 |
|
|
$ |
76,971 |
|
Property and equipment, net |
|
|
6,370 |
|
|
|
8,096 |
|
Operating and financing lease right-of-use assets |
|
|
14,055 |
|
|
|
16,547 |
|
Other assets |
|
|
3,728 |
|
|
|
3,500 |
|
Total assets |
|
$ |
209,581 |
|
|
$ |
105,114 |
|
Liabilities, convertible preferred stock, and stockholders' equity (deficit) |
|
|
|
|
|
|
||
Accounts payable and accrued expenses |
|
$ |
8,513 |
|
|
$ |
8,631 |
|
Operating and financing lease liabilities |
|
|
14,354 |
|
|
|
16,912 |
|
Simple agreements for future equity (SAFEs) |
|
|
— |
|
|
|
25,100 |
|
Other liabilities |
|
|
73 |
|
|
|
73 |
|
Total liabilities |
|
|
22,940 |
|
|
|
50,716 |
|
Convertible preferred stock |
|
|
— |
|
|
|
216,413 |
|
Stockholders' equity (deficit) |
|
|
186,641 |
|
|
|
(162,015 |
) |
Total liabilities, convertible preferred stock, and stockholders' equity (deficit) |
|
$ |
209,581 |
|
|
$ |
105,114 |
|
Artiva Biotherapeutics, Inc.
Condensed Statements of Operation and Comprehensive Loss
(unaudited)
(in thousands, except share and per share data)
|
|
Year Ended |
|
|||||
|
|
2024 |
|
|
2023 |
|
||
Revenue |
|
|
|
|
|
|
||
Collaboration revenue |
|
$ |
— |
|
|
$ |
32,923 |
|
License and development support revenue |
|
|
251 |
|
|
|
569 |
|
Total revenue |
|
|
251 |
|
|
|
33,492 |
|
Operating expenses: |
|
|
|
|
|
|
||
Research and development |
|
|
50,328 |
|
|
|
50,251 |
|
General and administrative |
|
|
17,205 |
|
|
|
13,912 |
|
Total operating expenses |
|
|
67,533 |
|
|
|
64,163 |
|
Loss from operations |
|
|
(67,282 |
) |
|
|
(30,671 |
) |
Other income, net |
|
|
|
|
|
|
||
Interest income |
|
|
5,349 |
|
|
|
2,535 |
|
Change in fair value of SAFEs |
|
|
(3,597 |
) |
|
|
(707 |
) |
Other income, net |
|
|
157 |
|
|
|
195 |
|
Total other income, net |
|
|
1,909 |
|
|
|
2,023 |
|
Loss before provision for income taxes |
|
|
(65,373 |
) |
|
|
(28,648 |
) |
Provision for income taxes |
|
|
— |
|
|
|
(72 |
) |
Net loss |
|
$ |
(65,373 |
) |
|
$ |
(28,720 |
) |
Net loss per share, basic and diluted |
|
$ |
(5.81 |
) |
|
$ |
(35.78 |
) |
Weighted-average common shares outstanding, basic and diluted |
|
|
11,258,851 |
|
|
|
802,747 |
|
Comprehensive loss: |
|
|
|
|
|
|
||
Net loss |
|
$ |
(65,373 |
) |
|
$ |
(28,720 |
) |
Other comprehensive income (loss) |
|
|
(437 |
) |
|
|
308 |
|
Comprehensive loss |
|
$ |
(65,810 |
) |
|
$ |
(28,412 |
) |
Contacts
Investors: Neha Krishnamohan, Artiva Biotherapeutics, ir@artivabio.com
Media: Jessica Yingling, Ph.D., Little Dog Communications Inc., jessica@litldog.com, +1.858.344.8091
Source: Artiva Biotherapeutics, Inc.